About Phoremost
Phoremost is a company based in Cambridge (United Kingdom) founded in 2015. Phoremost has raised $76.8 million across 6 funding rounds from investors including XtalPi, Cambridge Enterprise and Cambridge Angels. The company has 32 employees as of March 31, 2021. Phoremost offers products and services including SITESEEKER Technology. Phoremost operates in a competitive market with competitors including Rheonix, 64x Bio, reMYND, Molcure and Adaptyv Biosystems, among others.
- Headquarter Cambridge, United Kingdom
- Employees 32 as on 31 Mar, 2021
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Phoremost Limited
- Date of Incorporation 01 Apr, 2014
- Jurisdiction PAMPISFORD, UNITED KINGDOM
-
Annual Revenue
$1.04 M (USD)13as on Mar 31, 2022
-
Net Profit
-$10.31 M (USD)-61as on Mar 31, 2022
-
EBITDA
-$12.52 M (USD)-68as on Mar 31, 2022
-
Total Equity Funding
$76.8 M (USD)
in 6 rounds
-
Latest Funding Round
$12 M (USD), Series B
Sep 10, 2024
-
Investors
XtalPi
& 13 more
-
Employee Count
32
as on Mar 31, 2021
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Phoremost
Phoremost offers a comprehensive portfolio of products and services, including SITESEEKER Technology.
Tool for identifying novel targets in oncology and protein degradation fields
People of Phoremost
Unlock access to complete
Unlock access to complete
Funding Insights of Phoremost
Phoremost has successfully raised a total of $76.8M across 6 strategic funding rounds. The most recent funding activity was a Series B round of $12 million completed in September 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Phoremost
Phoremost has secured backing from 14 investors, including venture fund, angel, and institutional investors. Prominent investors backing the company include XtalPi, Cambridge Enterprise and Cambridge Angels.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Tech companies are invested in by Parkwalk venture capital firm.
|
Locked | Locked | Locked | |
|
Early & Growth stage tech & offline focused VC firm funding companies in the UK & Ireland
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Phoremost
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Phoremost
Investment portfolio details for Phoremost
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Phoremost
Detailed financials for Phoremost
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Phoremost Comparisons
Peer comparison for Phoremost
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Phoremost
Phoremost operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Rheonix, 64x Bio, reMYND, Molcure and Adaptyv Biosystems, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Instruments for automated molecular assays are developed using disposable cartridges.
|
|
| Locked | Locked | Locked |
Cell and gene therapies for multiple diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of a drug pipeline programs for neurodegenerative diseases
|
|
| Locked | Locked | Locked |
AI-based platform for drug discovery and antibody detection is provided.
|
|
| Locked | Locked | Locked |
Protein design, synthesis, testing, and validation services are offered.
|
Detailed competitors of Phoremost
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Phoremost
Complete news archive for Phoremost
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Phoremost
Phoremost was founded in 2015.
Phoremost is headquartered in Cambridge, United Kingdom. It is registered at Cambridge, Cambridgeshire, United Kingdom.
Phoremost is a funded company, having raised a total of $76.8M across 6 funding rounds to date.
As of Mar 31, 2021, the latest employee count at Phoremost is 32.
Annual revenue of Phoremost is $1.04M as on Mar 31, 2022.
Phoremost develops a phenotypic screening platform to identify specific targetspathways. The companys proprietary Protein Interference technology (PROTEINi) is a live-cell assay system that probes for the druggable sites across the whole human genome. It has also developed Site-Seekerplatform which is a phenotypic screening platform that identifies the new targets for drug development. Its lead therapeutic program has identified drug candidates to synthetic lethal target for KRAS which is a viral oncogene homolog.
Phoremost offers SITESEEKER Technology.
Phoremost has 14 investors. Key investors include XtalPi, Cambridge Enterprise, Cambridge Angels, Parkwalk, and BGF.